Of note, 10 out of the 24 novel fusions were confirmed in all control and tumour samples (Supplementary Fig. S1a) and its incidence on tumour development should be negligible; 13 out of 24 were only confirmed in a fraction of tumour and control samples and could be considered polymorphisms, in any case with limited functional capacity (Supplementary Fig. S1b); and only the NFYC-TAL1 fusion was confirmed exclusivelly in tumour 521 and could be considered as pathogenic (Fig. 2a). This evidence concerns the gene TAL1 and neoplasm.